Meta-analysis of randomized, controlled clinical trials in angiogenesis: Gene and cell therapy in peripheral arterial disease

Heart and Vessels

Volumn 24, Issue 5, 2009, Pages 321-328

  Haro, Joaquin ^a,b   Acin, Francisco ^a   Lopez Quintana, Alfonso ^a   Florez, Aurora ^a   Martinez Aguilar, Esther ^a   Varela, Cesar ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^b NONE   (Spain)

Author keywords

Angiogenesis; Gene therapy; Meta analysis; Peripheral vascular disease

Indexed keywords

ADENOVIRUS VECTOR; DEVELOPMENTALLY REGULATED ENDOTHELIAL CELL LOCUS 1 PROTEIN; PLACEBO; PLASMID VECTOR; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASOACTIVE AGENT;

ADVERSE OUTCOME; ANALGESIA; ANGIOGENESIS; ANGIOGENIC GENE THERAPY; ANKLE BRACHIAL INDEX; ARTERY DISEASE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPOTENSION; LEG ISCHEMIA; LIMB ISCHEMIA; LIMB SALVAGE; LOW DRUG DOSE; META ANALYSIS; MORTALITY; NEOPLASM; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; ULCER HEALING; VIRAL GENE DELIVERY SYSTEM; WALKING;

CELL TRANSPLANTATION; CLINICAL TRIALS, PHASE II AS TOPIC; DOUBLE-BLIND METHOD; GENE THERAPY; HUMANS; INTERMITTENT CLAUDICATION; ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; ODDS RATIO; PAIN; PAIN MEASUREMENT; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WALKING; WOUND HEALING;

EID: 70349634359     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-008-1140-z     Document Type: Review

References (33)

1. Girolami B, Bernardi E, Prins MH, ten Cate JW, Prandoni P, Simioni P, Andreozzi GM, Girolami A, Büller HR (2000) Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: A meta-analysis. Eur J Vasc Endovasc Surg 19(4):370-380
2. Collinson DJ, Donnelly R (2004) Therapeutic angiogenesis in peripheral arterial disease: Can biotechnology produce an effective collateral circulation? Eur J Vasc Endovasc Surg 28(1):9-23
3. Doi K, Ikeda T, Marui A, Kushibiki T, Arai Y, Hirose K, Soga Y, Iwakura A, Ueyama K, Yamahara K, Itoh H, Nishimura K, Tabata Y, Komeda M (2007) Enhanced angiogenesis by gelatin hydrogels incorporating basic fibroblast growth factor in rabbit model of hind limb ischemia. Heart Vessels 22(2):104-108
4. Sugihara S, Yamamoto Y, Matsubara K, Ishida K, Matsuura T, Ando F, Igawa G, Narazaki G, Miake J, Tajima F, Nishio R, Nakayama B, Igawa O, Shigemasa C, Hisatome I (2006) Autoperipheral blood mononuclear cell transplantation improved giant ulcers due to chronic arteriosclerosis obliterans. Heart Vessels 21(4):258-262
5. Pu LQ, Sniderman AD, Arekat Z, Graham AM, Brassard R, Symes JF (1993) Angiogenic growth factor and revascularization of the ischemic limb: evaluation in a rabbit model. J Surg Res 54(6):575-583
6. Takeshita S, Pu LQ, Stein LA, Sniderman AD, Bunting S, Ferrara N, Isner JM, Symes JF (1994) Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 90(5 Pt 2):II228-II234
7. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM (1994) Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93(2):662-670
8. Wahlberg E (2003) Angiogenesis and arteriogenesis in limb ischemia. J Vasc Surg 38(1):198-203
9. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Walsh K, Symes JF (1996) Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348(9024):370-374
10. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM (1998) Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97(12): 1114-1123
11. Isner JM, Baumgartner I, Rauh G, Schainfeld R, Blair R, Manor O, Razvi S, Symes JF (1998) Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results. J Vasc Surg 28(6):964-973
12. Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG (2001) Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 1104(7):753-755
13. Shyu KG, Chang H, Wang BW, Kuan P (2003) Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med 114(2):85-92
14. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17(1):1-12
15. Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273(5):408-412
16. Cooper LT, Hiatt WR, Creager MA, Regensteiner JG, Casscells W, Isner JM, Cooke JP, Hirsch AT (2001) Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. Vasc Med 6(4):235-239
17. Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J, Sequeira R, Kent CK, Bacchetta M, Goldman C, Salenius JP, Schmieder FA, Pilsudski R (2002) Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 35(5):930-936
18. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH; TRAFFIC Investigators (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet 359(9323):2053-2058
19. Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH (2003) Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108(16):1933-1938
20. Lazarous DF, Unger EF, Epstein SE, Stine A, Arevalo JL, Chew EY, Quyyumi AA (2000) Basic fibroblast growth factor in patients with intermittent claudication: Results of a phase I trial. J Am Coll Cardiol 36(4):1239-1244
21. Grossman PM, Mendelsohn F, Henry TD, Hermiller JB, Litt M, Saucedo JF, Weiss RJ, Kandzari DE, Kleiman N, Anderson RD, Gottlieb D, Karlsberg R, Snell J, Rocha-Singh K (2007) Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Am Heart J 153(5):874-880
22. Makinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E, Yla-Herttuala S (2002) Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: A randomized, placebo-controlled, double-blinded phase II study. Mol Ther 6(1):127-133
23. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T; Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators (2002) Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 360(9331):427-435
24. Gardner AW, Skinner JS, Cantwell BW, Smith LK (1991) Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc 23(4):402-408
25. Laham RJ, Chronos NA, Pike M, Leimbach ME, Udelson JE, Pearlman JD, Pettigrew RI, Whitehouse MJ, Yoshizawa C, Simons M (2000) Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study. J Am Coll Cardiol 36(7):2132-2139
26. European Agency for Evaluation of Medical Products. CPMP/EWP/714/ 98rev.1. Note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease. European Agency for Evaluation of Medical Products; 2002
27. Hiatt WR, Cox L, Greenwalt M, Griffin A, Schechter C (2005) Quality of the assessment of primary and secondary endpoints in claudication and critical leg ischemia trials. Vasc Med 10(3):207-213
28. Rana JS, Mannam A, Donnell-Fink L, Gervino EV, Sellke FW, Laham RJ (2005) Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am J Cardiol 95(12):1456-1459
29. Simons M (2005) Angiogenesis: Where do we stand now? Circulation 111(12):1556-1566
30. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, Morishita R, Annex BH (2008) Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 118(1):58-65
31. Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K, Matsumoto K, Nakamura T, Kaneda Y, Ogihara T (2001) Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: Molecular mechanisms of delayed angiogenesis in diabetes. Circulation 104(19):2344-2350
32. Epstein SE, Fuchs S, Zhou YF, Baffour R, Kornowski R (2001) Therapeutic interventions for enhancing collateral development by administration of growth factors: Basic principles, early results and potential hazards. Cardiovasc Res 49(3):532-542
33. Namba T, Koike H, Murakami K, Aoki M, Makino H, Hashiya N, Ogihara T, Kaneda Y, Kohno M, Morishita R (2003) Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 108(18):2250-2257